Cardiac Biotech Solutions Inc.

Cardiac Biotech Solutions Inc.

CBSC
Cardiac Biotech Solutions Inc.US flagOther OTC
0.03
USD
- -
- -
3.38MMarket Cap

Total Valuation

Cardiac Biotech Solutions Inc. carries a market capitalization of 3.38M, placing it among publicly traded companies globally. Its enterprise value stands at 4.39M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.38M
Enterprise Value4.39M

Share Statistics

Cardiac Biotech Solutions Inc. currently has 158.61M shares outstanding.

Shares Outstanding158.61M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 72.43, and the price-to-book ratio stands at -0.26.

PE RatioN/A
PS Ratio72.43
PB Ratio-0.26
P/TBV Ratio-3.80
P/FCF Ratio-4.51
P/OCF Ratio-4.51

Enterprise Valuation

EV / Sales72.22
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

Cardiac Biotech Solutions Inc. maintains a current ratio of 0.15, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -12.36, indicating conservative leverage, while an interest coverage ratio of -95.32 demonstrates limited ability to service its debt obligations.

Current Ratio0.15
Quick Ratio0.12
Debt / Equity-12.36
Debt / EBITDA-0.10
Interest Coverage-95.32

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)-652.18
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory TurnoverN/A

Stock Price Statistics

Cardiac Biotech Solutions Inc.'s stock has declined approximately -18.91892% over the past 52 weeks. The 50-day moving average sits at 0.04, while the 200-day moving average is 0.04.

Beta (5Y)N/A
52-Week Price Change-18.91892%
50-Day Moving Average0.04
200-Day Moving Average0.04
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Cardiac Biotech Solutions Inc. generated 60,718.00 in revenue and converted that into -1.43M in net income, yielding earnings per share of -0.01. EBITDA reached -1.45M, while operating income came in at -1.45M.

Revenue60,718.00
Gross Profit60,718.00
Operating Income-1.45M
Pretax Income-1.43M
Net Income-1.43M
EBITDA-1.45M
EBIT-1.45M
Earnings Per Share (EPS)-0.01

Balance Sheet

Cardiac Biotech Solutions Inc. holds 155,975.00 in cash and equivalents against 143,261.00 in total debt, resulting in a net debt position of -12,714.00. Total book value stands at -16.78M, with working capital of -1.13M providing operational flexibility.

Cash & Cash Equivalents155,975.00
Total Debt143,261.00
Net Debt-12,714.00
Equity (Book Value)-16.78M
Book Value Per Share-0.11
Working Capital-1.13M

Cash Flow

Cardiac Biotech Solutions Inc. produced -974,891.00 in operating cash flow over the past twelve months.

Operating Cash Flow-974,891.00
Capital ExpendituresN/A
Free Cash Flow-974,891.00
FCF Per Share-0.01

Margins

Cardiac Biotech Solutions Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -2,383.73 and net profit margin of -2,347.26 provide insight into operational efficiency.

Gross Margin100.00
Operating Margin-2,383.73
Pretax Margin-2,347.26
Profit Margin-2,347.26
EBITDA Margin-2,383.73

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-25.64
FCF Yield-22.17

Stock Splits

Cardiac Biotech Solutions Inc.'s most recent stock split took place on February 16, 2016 with a 75:1 split ratio.

Last Split Date2/16/2016
Split Ratio75:1

Scores

Cardiac Biotech Solutions Inc. posts an Altman Z-Score of -105.76, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-105.76